The Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Confirmed Its June 2024 Negative Opinion On Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy Secondary To Age-related Macular Degeneration
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency's Committee for Medicinal Products for Human Use has upheld its negative opinion on Apellis Pharmaceuticals' intravitreal pegcetacoplan for treating geographic atrophy secondary to age-related macular degeneration.
September 20, 2024 | 9:02 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The European Medicines Agency's committee has confirmed its negative opinion on Apellis Pharmaceuticals' pegcetacoplan, impacting its potential market approval in Europe.
The confirmation of a negative opinion by the EMA's committee significantly reduces the likelihood of pegcetacoplan's approval in Europe, which could negatively impact Apellis Pharmaceuticals' stock price due to reduced market potential and investor sentiment.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90